scholarly journals Hepatitis C, hepatitis B and HIV infection among Egyptian prisoners: Seroprevalence, risk factors and related chronic liver diseases

2013 ◽  
Vol 6 (3) ◽  
pp. 186-195 ◽  
Author(s):  
Hala I. Mohamed ◽  
Zienab M. Saad ◽  
Ehab M. Abd-Elreheem ◽  
Wael M. Abd-ElGhany ◽  
Mohamed S. Mohamed ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Hiv Infection ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases

Silymarin in the treatment of chronic liver diseases: past and future

2008 ◽  
Vol 149 (51) ◽  
pp. 2413-2418 ◽  
Author(s):  
János Fehér ◽  
Gabriella Lengyel
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases

Az idült májbetegségek kezelésére csak a kóroki folyamatok ismeretében tudunk célzott terápiát választani. Az oxidatív stressz okozta májkárosodásban (alkoholos és nem alkoholos májbetegség, gyógyszer és vegyszer okozta megbetegedések) az antioxidáns tulajdonságú szerek, mint például a silymarin, a vírusos eredetű krónikus hepatitisekben (hepatitis B- és hepatitis C-vírus-fertőzés) pedig a kombinált peginterferon + nukleozidanalóg kezelés az elsődlegesen választandó szer. A silymarin fő tulajdonságai: membránstabilizáló és antioxidáns hatás, elősegíti a májsejt-regenerációt, csökkenti a gyulladásos aktivitást és gátolja a fibrogenezist. Mindezt kísérletes és klinikai vizsgálatok is igazolták. Nyílt vizsgálatok szerint a silymarin tartós alkalmazása az alkoholos eredetű májcirrhosisban szenvedő betegek túlélési idejét jelentős mértékben növelte. Legújabban kimutatták, hogy nagy dózisú silibinininfúzió hepatitis C-vírus okozta krónikus hepatitisben négyhetes kezelés során jelentős mértékben csökkentette a hepatitis C-vírus-számot. A legújabb molekuláris biológiai vizsgálatok igazolták, hogy a silymarin, a fenti korábban bizonyított hatása mellett, jelentős mértékben képes csökkenteni a daganatossejt-proliferációt, az angiogenezist, valamint az inzulinrezisztenciát. Mindezen tulajdonságok alapján a mai korszerű betegellátásban a silymarinkészítmények alkalmazása a krónikus májbetegségek kezelésében, elsősorban az alkoholos és nem alkoholos steatohepatitisben, helyénvaló és várhatóan a jövőben is az lesz. Bizonyos tumoros betegségekben pedig adjuváns kezelésként kerülhetnek alkalmazásra.

scholarly journals Burden of Liver Diseases: A Review from Iran

2019 ◽  
Vol 11 (4) ◽  
pp. 189-191
Author(s):  
Amir Anushiravani ◽  
Sadaf Ghajarieh Sepanlou
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Fatty Liver Disease ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Alcoholic Fatty Liver ◽  
Alcoholic Fatty Liver Disease

There has been an increase in the burden of liver diseases in Iran, with an increasing trend from communicable to non-communicable diseases. Almost 5400 deaths were due to chronic liver diseases in 2017. We aim to provide a concise update on the epidemiological trends of liver diseases in Iran. Estimations of deaths, disability-adjusted life years, prevalence of chronic liver diseases and cirrhosis in Iran with its common etiologies have been reported. We investigated the major causes of chronic liver diseases in Iran, we have reported our hepatology research centers, and also we have depicted the future of liver diseases in Iran. In 2017, there was a rising trend in chronic liver diseases in Iran. The most common etiologies for chronic liver disease were chronic hepatitis B, chronic hepatitis C, and non-alcoholic steatohepatitis with highest mortalities due to liver cancer and hepatitis C. The prevalence of HBV infection has decreased from 2.9% to 1.3% with effective vaccination, but new cases are still seen due to perinatal transmission. Treatment of HCV has dramatically changed with new drugs which are being produced by local pharmaceuticals at a low cost. The main obstacle in its elimination is finding patients and linkage to care. More than a third of our population have non-alcoholic fatty liver disease in which central obesity had a stronger association than weight itself. Iran has a high burden of liver diseases. The Ministry of Health has effectively controlled hepatitis B and is working towards the World Health WHO’s goals for hepatitis C by 2030. This being said, non-alcoholic fatty liver disease is becoming a major threat to our nation’s health and quality of life.

scholarly journals Iron Overload andHFEGene Mutations in Czech Patients with Chronic Liver Diseases

2012 ◽  
Vol 32 (1) ◽  
pp. 65-72 ◽  
Author(s):  
Marketa Dostalikova-Cimburova ◽  
Karolina Kratka ◽  
Jaroslav Stransky ◽  
Ivana Putova ◽  
Blanka Cieslarova ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Disease ◽  
Hepatitis C ◽  
Hepatitis B ◽  
Iron Overload ◽  
Alcoholic Liver Disease ◽  
Liver Diseases ◽  
Gene Mutations ◽  
Chronic Liver ◽  
Chronic Liver Diseases

The aim of the study was to identify the prevalence ofHFEgene mutations in Czech patients with chronic liver diseases and the influence of the mutations on iron status. The presence ofHFEgene mutations (C282Y, H63D, and S65C) analyzed by the PCR-RFLP method, presence of cirrhosis, and serum iron indices were compared among 454 patients with different chronic liver diseases (51 with chronic hepatitis B, 122 with chronic hepatitis C, 218 with alcoholic liver disease, and 63 patients with hemochromatosis). Chronic liver diseases patients other than hemochromatics did not have an increased frequency ofHFEgene mutations compared to controls. Although 33.3% of patients with hepatitis B, 43% of patients with hepatitis C, and 73.2% of patients with alcoholic liver disease had elevated transferrin saturation or serum ferritin levels, the presence ofHFEgene mutations was not significantly associated with iron overload in these patients. Additionally, patients with cirrhosis did not have frequencies ofHFEmutations different from those without cirrhosis. This study emphasizes the importance, not only of C282Y, but also of the H63D homozygous genetic constellation in Czech hemochromatosis patients. Our findings show that increased iron indices are common in chronic liver diseases butHFEmutations do not play an important role in the pathogenesis of chronic hepatitis B, chronic hepatitis C, and alcoholic liver disease.

scholarly journals Prevalence and Risk Factors of Hepatitis B and Hepatitis C Virus Infections among Patients with Chronic Liver Diseases in Public Hospitals in Addis Ababa, Ethiopia

2013 ◽  
Vol 2013 ◽  
pp. 1-7 ◽  
Author(s):  
Abel Girma Ayele ◽  
Solomon Gebre-Selassie
Keyword(s):  
Hepatitis C ◽  
Hepatitis B ◽  
Surface Antigen ◽  
Liver Diseases ◽  
Addis Ababa ◽  
Hepatitis B Surface Antigen ◽  
Chronic Liver ◽  
Public Hospitals ◽  
Virus Infections ◽  
Chronic Liver Diseases

Background and Aims. Hepatitis B and hepatitis C viruses are major public health problems worldwide. The aim of this study was to determine the prevalence and risk factors of hepatitis B and C virus infections in patients with chronic liver diseases in three public hospitals in Addis Ababa City, Ethiopia. Methods. The study was conducted on 120 clinically diagnosed chronic liver disease patients. Possible associated factors with infections by the viruses were collected from patient using questionnaire. Serum was screened for the presence of hepatitis B surface antigen and antihepatitis C virus antibodies using qualitative immunochromatographic method. Results. Hepatitis B surface antigen was detected in 43 (35.8%) and anti-HCV antibody 27 (22.5%) patients clinically diagnosed to have chronic liver diseases. Hepatitis B virus infection was higher in males 29/76 (38.2%) compared to 14/44 (31.8%) females, while antihepatitis C virus antibody was higher in females 13/44 (29.5%) compared to 14/76 (18.4%) males. Of the study participants, 3 (2.5%) had dual hepatitis B and C virus coinfection. Conclusion. The prevalence of hepatitis B surface antigen and anti-HCV antibody was high in patients below 50 years of age. Dental extraction procedure at health facility was associated with hepatitis C virus infection (OR, 2.95; 95% CI, 1.21–7.17, ).

scholarly journals Pilot study of hepatitis b, c and human immunodeficiency viruses infections among patients with chronic liver diseases from north-east india attending a new tertiary care health set up at shillong

2017 ◽  
Vol 69 (1) ◽  
pp. 18
Author(s):  
Jeetendra Gurung ◽  
Anil Chandra Phukan ◽  
Annie B. Khyriem ◽  
Kyrshanlang G. Lynrah
Keyword(s):  
Public Health ◽  
Risk Factors ◽  
Hepatitis B ◽  
Liver Diseases ◽  
Hiv Infections ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
North East India ◽  
North East ◽  
North Eastern

<p class="ABS"><span class="ABS_Bold-Italic" lang="en-GB">Background:</span> Chronic liver diseases (CLD) are major public health concerns in North-Eastern India. Association of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) infections in CLD patients result in atypical presentations with increased severity and duration of illness. Understanding of agent, host, clinical profiles and their co-relationship for better management and prevention of such diseases in the community are important challenges. <span class="ABS_Bold-Italic" lang="en-GB">Aims:</span> To assess sero-prevalance of HBV, HCV, HIV and their co-infection/triple infection in CLD patients from North-East India. To determine risk factors predisposing to development of CLDs. To find out if any correlation exists between risk factors for CLDs and that of HBV/HCV/HIV infections. <span class="ABS_Bold-Italic" lang="en-GB">Materials And Methods:</span> This study was conducted from December 2009 to June 2011 in North-Eastern Indira Gandhi Regional Institute of Health and Medical Sciences. Blood samples were collected from 57 clinically diagnosed CLD patients after obtaining Institutional ethical clearance. Detail clinical profile with relevant biochemical test results were recorded. Viral markers - hepatitis B surface antigen, hepatitis B e (HBe) antigen, anti-HBe and anti-HCV were assessed employing commercial ELISA kits. Specimens were subjected for detection and confirmation of HIV infection as per NACO Guidelines. <span class="ABS_Bold-Italic" lang="en-GB">Results:</span> Male to female ratio was 1.85:1 with most cases in range of 31-50 years. HBV markers were detected in 35 (61.40%) and anti-HCV in 2 (3.5%) patients. Anti-HIV was reactive in 7 (12.28%) patients; 4 co-infected with HBV and 2 with HCV. <span class="ABS_Bold-Italic" lang="en-GB">Conclusion:</span> HBV is still a major cause of CLD, followed by HCV in North-East India. Co-infection of HBV/HCV with HIV was low (7.14%) in comparison to rest of India. Confections of HIV with HBV/HCV in CLDs patients was observed to be major public health concern in terms of risk factors and transmission dynamics of these chronic diseases in North-East India.</p><div> </div>

scholarly journals Physicians’ Practices for Diagnosing Liver Fibrosis in Chronic Liver Diseases: A Nationwide, Canadian Survey

2014 ◽  
Vol 28 (1) ◽  
pp. 23-30 ◽  
Author(s):  
Giada Sebastiani ◽  
Peter Ghali ◽  
Philip Wong ◽  
Marina B Klein ◽  
Marc Deschenes ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Liver Biopsy ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Noninvasive Methods ◽  
Routine Assessment

OBJECTIVE: To determine practices among physicians in Canada for the assessment of liver fibrosis in patients with chronic liver diseases.METHODS: Hepatologists, gastroenterologists, infectious diseases specialists, members of the Canadian Gastroenterology Association and/or the Canadian HIV Trials Network who manage patients with liver diseases were invited to participate in a web-based, national survey.RESULTS: Of the 237 physicians invited, 104 (43.9%) completed the survey. Routine assessment of liver fibrosis was requested by the surveyed physicians mostly for chronic hepatitis C (76.5%), followed by autoimmune/cholestatic liver disease (59.6%) and chronic hepatitis B (52.9%). Liver biopsy was the main diagnostic tool for 46.2% of the respondents, Fibroscan (Echosens, France) for 39.4% and Fibrotest (LabCorp, USA) for 7.7%. Etiology-specific differences were observed: noninvasive methods were mostly used for hepatitis C (63% versus 37% liver biopsy) and hepatitis B (62.9% versus 37.1% liver biopsy). For 42.7% of respondents, the use of noninvasive methods reduced the need for liver biopsy by >50%. Physicians’ characteristics associated with higher use of noninvasive methods were older age and being based at a university hospital or in private practice versus community hospital. Physicians’ main concerns regarding noninvasive fibrosis assessment methods were access/availability (42.3%), lack of guidelines for clinical use (26.9%) and cost/lack of reimbursement (14.4%).CONCLUSIONS: Physicians who manage patients with chronic liver diseases in Canada require routine assessment of liver fibrosis stage. Although biopsy remains the primary diagnostic tool for almost one-half of respondents, noninvasive methods, particularly Fibroscan, have significantly reduced the need for liver biopsy in Canada. Limitations in access to and availability of the noninvasive methods represent a significant barrier. Finally, there is a need for clinical guidelines and a better reimbursement policy to implement noninvasive tools to assess liver fibrosis.

scholarly journals Serum ischemic modified albumin (IMA) concentration and IMA/albumin ratio in patients with hepatitis B-related chronic liver diseases

2017 ◽  
Vol 47 ◽  
pp. 947-953 ◽  
Author(s):  
Fatma YAVUZ ◽  
Murat BIYIK ◽  
Mehmet ASIL ◽  
Ramazan DERTLİ ◽  
Ali DEMİR ◽  
...  
Keyword(s):  
Hepatitis B ◽  
Liver Diseases ◽  
Chronic Liver ◽  
Chronic Liver Diseases ◽  
Albumin Ratio
Sign in / Sign up

Export Citation Format

Share Document